Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Boston Scientific Corporation : BSX, ABT, ZMH, and ETRM Under StockCall’s Microscope

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2013 | 02:00pm CEST

StockCall.com Provides Stock Research on Boston Scientific Corp., Abbott Laboratories, Zimmer Holdings Inc., and EnteroMedics Inc.

New York City, New York -- (May 02, 2013)

The Supreme Court, last year, upheld the Affordable Care Act (ACA), which is the biggest overhaul of the healthcare industry in decades. While the healthcare industry has generally supported ACA, some features of the act have faced criticism. One such feature is the 2.3% tax on gross U.S. sales of medical devices. Medical appliances & equipment makers say that the tax will lead to higher costs for them, hurting innovation. While the Senate voted in favor of repealing the 2.3% tax, it is unlikely that the tax will be repealed. Shares of medical appliances & equipment companies ended mostly lower on Wednesday, tracking losses in the broad market. Among the major movers were Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), and EnteroMedics Inc. (NASDAQ: ETRM). StockCall has released full comprehensive research on BSX, ABT, ZMH, and ETRM and these free technical analyses can be downloaded by signing up at

www.stockcall.com/technicalanalysis

Shares of Boston Scientific Corporation fluctuated between gains and losses on Wednesday before finishing the day flat at $7.49 on volume of 12.95 million. Shares of the company have traded sideways this week. However, year-to-date, the stock has had an excellent run, jumping more than 30.70% as compared to a gain of nearly 11% for the S&P 500. BSX?s shares are currently trading nearly 5.80% below their 52-week high. Free technical analysis on BSX available by signing up at

www.StockCall.com/BSX050213.pdf

Shares of Abbott Laboratories edged lower in Wednesday?s trading session, however, the losses were limited. The stock ended the day 0.08% lower at $36.89 on volume of 5.46 million after trading between $36.62 and $37.20. Despite the pullback, Abbott?s shares are up nearly 1.20% for the week. The stock has gained more than 18.50% so far in 2013, outperforming the S&P 500. However, shares of ABT have been struggling to break through $37.50 resistance level. The stock is currently trading well above its 50-day and 200-day moving averages. Register today and access the free research on ABT at

www.StockCall.com/ABT050213.pdf

Zimmer Holdings Inc.?s shares also slipped in trading on Wednesday, tracking losses in the broad market. The stock closed 1.50% lower at $75.30 on volume of 617,800. Despite the pullback, the company?s shares are currently trading close to their 52-week high of $77.53. Shares of ZMH have been facing resistance at around $76.50. The stock currently has strong support at around $73. Zimmer?s shares are currently trading well above their 50-day and 200-day moving averages which suggests that market sentiment is bullish on the stock. The positive trend is further confirmed by recent volume activity. The free report on ZMH can be downloaded by signing up now at

www.StockCall.com/ZMH050213.pdf

Shares of EnteroMedics Inc. tumbled in Wednesday?s trading session after the company reported its financial results for the first quarter. The stock closed 9.59% lower at $0.868 on above average volume of 601,300 after touching an intra-day low of $0.86. Shares of ETRM are currently trading close to their 52-week low of $0.81. Year-to-date, the stock has now fallen nearly 69%. Most of the losses came in mid-February when the stock saw a huge sell-off. EnteroMedics? shares have now slipped below their 50-day moving average. Free report on ETRM can be accessed by registering at

www.StockCall.com/ETRM050213.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: [email protected]

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BOSTON SCIENTIFIC CORPORAT
05/26 BOSTON SCIENTIFIC : Positive Results For Post Approval Clinical Trial of Bronchi..
05/25 BOSTON SCIENTIFIC : Announces Positive European Registry Results For WATCHMAN Le..
05/25 BOSTON SCIENTIFIC : Trademark Application for "ISIZE" Filed
05/25 BOSTON SCIENTIFIC : LOTUS Valve System Demonstrated Superior Efficacy to CoreVal..
05/25 BOSTON SCIENTIFIC : Closes Symetis Acquisition
05/25 POSITIVE RESULTS FOR POST APPROVAL C : Bsx)
05/24 BOSTON SCIENTIFIC : Announces Positive Outcomes From Prospective Study Of Bronch..
05/23 BOSTON SCIENTIFIC : Special Notice - 65-- Ultra Ice Plus & Other Catheters
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22 BOSTON SCIENTIFIC : The Sample Preparation Market Shows Strength in the Medical ..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
05/17 PHILIPS CEO : uptake of connected care products progressing slowly
05/15DJMARKET SNAPSHOT : Stock Market Sets Fresh Records As Oil Rallies
05/15 Thermo Fisher to buy Patheon for $5.2 billion to expand biopharma services
05/15DJMARKET SNAPSHOT : Stock Market Sets New Records As Oil Rallies
05/15 European shares supported by oil bounce; cybersecurity stocks gain
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
05/24 Study confirms efficacy of Boston Sci's Alair system for severe asthma
05/19 Boston Scientific Corporation (BSX) Investor Presentation - Slideshow
05/16 Lotus Blooms In Phase III
05/16 Premarket analyst action - healthcare
05/16 Boston Scientific's LOTUS valve beats Medtronic's CoreValve in late-stage stu..
Advertisement
Financials ($)
Sales 2017 8 868 M
EBIT 2017 2 176 M
Net income 2017 1 333 M
Debt 2017 4 476 M
Yield 2017 -
P/E ratio 2017 29,46
P/E ratio 2018 24,85
EV / Sales 2017 4,72x
EV / Sales 2018 4,27x
Capitalization 37 412 M
More Financials
Chart BOSTON SCIENTIFIC CORPORAT
Duration : Period :
Boston Scientific Corporat Technical Analysis Chart | BSX | US1011371077 | 4-Traders
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 29,4 $
Spread / Average Target 7,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael F. Mahoney Chairman, President & Chief Executive Officer
Edward Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Ian Meredith Global Chief Medical Officer & Executive VP
Nelda J. Connors Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BOSTON SCIENTIFIC CORP..26.31%37 412
THERMO FISHER SCIENTIF..22.54%67 845
DANAHER CORPORATION8.43%58 584
INTUITIVE SURGICAL, IN..43.55%33 538
PHILIPS8.28%32 627
ILLUMINA, INC.37.39%25 736
More Results